US Pharma MarketingUnder its new chief, Karen Massey, Argenx is positioning its blockbuster Vyvgart to become the Keytruda of the autoimmune disease space.
A single drug made Argenx one of the most valuable biotechs in Europe. Its new CEO is ready for the next act.
Under its new chief, Karen Massey, Argenx is positioning its blockbuster Vyvgart to become the Keytruda of the autoimmune disease space.
Source: PharmaVoice